EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

LRRK2 inhibitors and their potential in the treatment of Parkinson’s disease: current perspectives

Farzaneh Atashrazm, Nicolas Dzamko

Clinical Pharmacology: Advances and Applications · 2016

DOI: 10.2147/cpaa.s102191 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Pharmacology: Advances and Applications, 2016. Verfasst von Farzaneh Atashrazm und 1 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience Research Australia, Randwick. Die Arbeit wurde bisher 32-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Rabautophagyinflammationinhibitorlysosomesynuclein

Autor:innen und Institutionen

  • Neuroscience Research Australia, Randwick.
  • School of Medical Sciences, Faculty of Medicine, University of New South Wales, Kensington, NSW, Australia.

Zitieren

APA

Atashrazm, F., & Dzamko, N. (2016). LRRK2 inhibitors and their potential in the treatment of Parkinson’s disease: current perspectives. Clinical Pharmacology: Advances and Applications. https://doi.org/10.2147/cpaa.s102191

Vancouver

Atashrazm F, Dzamko N. LRRK2 inhibitors and their potential in the treatment of Parkinson’s disease: current perspectives. Clinical Pharmacology: Advances and Applications. 2016. doi:10.2147/cpaa.s102191

BibTeX
@article{Atashrazm2016,
  author = {Atashrazm, Farzaneh and Dzamko, Nicolas},
  title = {LRRK2 inhibitors and their potential in the treatment of Parkinson’s disease: current perspectives},
  journal = {Clinical Pharmacology: Advances and Applications},
  year = {2016},
  doi = {10.2147/cpaa.s102191}
}
Kostenlos starten →